IGF-1 vs insulin: Respective roles in modulating sodium transport via the PI-3 kinase/Sgk1 pathway in a cortical collecting duct cell line  E. Gonzalez-Rodriguez,

Slides:



Advertisements
Similar presentations
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduction of Hyaluronan-CD44–Mediated Growth, Migration,
Advertisements

The chemokine CCL2 activates p38 mitogen-activated protein kinase pathway in cultured rat hippocampal cells  Jungsook Cho, Donna L. Gruol  Journal of.
Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway  William A. Wilmer, Cynthia L. Dixon, Courtney Hebert 
Volume 56, Issue 5, Pages (November 1999)
Volume 68, Issue 4, Pages (October 2005)
Copyright © 2010 American Medical Association. All rights reserved.
From: IGF-1 Regulates the Extracellular Level of Active MMP-2 and Promotes Müller Glial Cell Motility Invest. Ophthalmol. Vis. Sci ;56(11):
Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells  Y. Huang, N.A. Noble, J. Zhang, C. Xu, W.A.
Volume 70, Issue 8, Pages (October 2006)
Volume 41, Issue 4, Pages (October 2004)
Volume 129, Issue 2, Pages (August 2005)
Volume 79, Issue 8, Pages (April 2011)
Glutamate signaling in chondrocytes and the potential involvement of NMDA receptors in cell proliferation and inflammatory gene expression  T. Piepoli,
Volume 66, Issue 4, Pages (October 2004)
Early aldosterone up-regulated genes: New pathways for renal disease?
Volume 63, Issue 1, Pages (January 2003)
Volume 53, Issue 5, Pages (May 1998)
Phosphoinositide 3-kinase inhibitors protect mouse kidney cells from cyclosporine- induced cell death  E. Sarró, O. Tornavaca, M. Plana, A. Meseguer, E.
Volume 69, Issue 4, Pages (February 2006)
Volume 98, Issue 3, Pages (August 1999)
Volume 63, Issue 2, Pages (February 2003)
C. Jacques, Ph. D. , A. D. Recklies, Ph. D. , A. Levy, F. Berenbaum, M
M.A. Greene, R.F. Loeser  Osteoarthritis and Cartilage 
Volume 79, Issue 8, Pages (April 2011)
Volume 25, Issue 4, Pages (December 2018)
Renin-stimulated TGF-β1 expression is regulated by a mitogen-activated protein kinase in mesangial cells  Y. Huang, N.A. Noble, J. Zhang, C. Xu, W.A.
Volume 129, Issue 2, Pages (August 2005)
Volume 56, Issue 5, Pages (November 1999)
Angiotensin II-induced growth of vascular smooth muscle cells requires an Src- dependent activation of the epidermal growth factor receptor1  Dirk Bokemeyer,
Volume 94, Issue 5, Pages (November 2018)
Basolateral carbonic anhydrase IV in the proximal tubule is a glycosylphosphatidylinositol-anchored protein  J.M. Purkerson, A.M. Kittelberger, G.J. Schwartz 
Evidence for low-density lipoprotein–induced expression of connective tissue growth factor in mesangial cells  Mimi Sohn, Yan Tan, Richard L. Klein, Ayad.
Volume 73, Issue 8, Pages (April 2008)
PDGF regulates gap junction communication and connexin43 phosphorylation by PI 3- kinase in mesangial cells  Jian Yao, Tetsuo Morioka, Takashi Oite  Kidney.
Role of meprin A in renal tubular epithelial cell injury
Volume 74, Issue 12, Pages (December 2008)
Volume 41, Issue 2, Pages (January 2011)
Volume 68, Issue 4, Pages (October 2005)
E. Boulanger, N. Grossin, M.-P. Wautier, R. Taamma, J.-L. Wautier 
Arachidonic acid induces ERK activation via Src SH2 domain association with the epidermal growth factor receptor  L.D. Alexander, Y. Ding, S. Alagarsamy,
Volume 128, Issue 4, Pages (April 2005)
Volume 72, Issue 2, Pages (July 2007)
Volume 1, Issue 3, Pages (February 1998)
Glutamate signaling in chondrocytes and the potential involvement of NMDA receptors in cell proliferation and inflammatory gene expression  T. Piepoli,
Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway  William A. Wilmer, Cynthia L. Dixon, Courtney Hebert 
Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells  Ingeborg A. Hauser,
Contribution of Src-FAK signaling to the induction of connective tissue growth factor in renal fibroblasts  A. Graness, I. Cicha, M. Goppelt-Struebe 
Volume 62, Issue 2, Pages (August 2002)
P. Harding, L. Balasubramanian, J. Swegan, A. Stevens, W.F. Glass 
Volume 70, Issue 4, Pages (August 2006)
Volume 72, Issue 5, Pages (September 2007)
Olivier Micheau, Jürg Tschopp  Cell 
Urate transport via human PAH transporter hOAT1 and its gene structure
Volume 70, Issue 10, Pages (November 2006)
Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells  Gur P. Kaushal, Varsha Kaushal, Ph.D., Xiaoman.
Volume 61, Issue 6, Pages (June 2002)
Human Keratinocytes Respond to Osmotic Stress by p38 Map Kinase Regulated Induction of HSP70 and HSP27  M. Garmyn, A. Pupe  Journal of Investigative Dermatology 
Volume 79, Issue 4, Pages (February 2011)
Jens Gaedeke, Nancy A. Noble, Wayne A. Border  Kidney International 
Volume 76, Issue 1, Pages (July 2009)
Volume 67, Issue 6, Pages (June 2005)
Volume 56, Issue 5, Pages (November 1999)
Volume 70, Issue 5, Pages (September 2006)
Modulation of renal epithelial barrier function by mitogen-activated protein kinases (MAPKs): Mechanism of cyclosporine A–induced increase in transepithelial.
Volume 58, Issue 1, Pages (July 2000)
Volume 70, Issue 8, Pages (October 2006)
IL-1β induces VEGF, independently of PGE2 induction, mainly through the PI3-K/mTOR pathway in renal mesangial cells  D. Solà-Villà, M. Camacho, R. Solà,
Volume 60, Issue 3, Pages (September 2001)
Volume 71, Issue 8, Pages (April 2007)
Gα12 and Gα13 Interact with Ser/Thr Protein Phosphatase Type 5 and Stimulate Its Phosphatase Activity  Yoshiaki Yamaguchi, Hironori Katoh, Kazutoshi Mori,
Presentation transcript:

IGF-1 vs insulin: Respective roles in modulating sodium transport via the PI-3 kinase/Sgk1 pathway in a cortical collecting duct cell line  E. Gonzalez-Rodriguez, H.-P. Gaeggeler, B.C. Rossier  Kidney International  Volume 71, Issue 2, Pages 116-125 (January 2007) DOI: 10.1038/sj.ki.5002018 Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 1 Time course of insulin and IGF-1-induced changes in transepithelial Na+ currents. Cells were treated at t0 with: vehicle (x, X), IGF-1 (0.6nM, open circle) or insulin (60nM, closed circle). The delta of the induced current as respect to t=0 (Isc stimulated-Isc at t=0) is represented. Kidney International 2007 71, 116-125DOI: (10.1038/sj.ki.5002018) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 2 Dose–response of insulin and IGF-1-induced changes in transepithelial Na+ currents. Dose–response for (a) insulin or (b) IGF-1. The delta of the induced current as respect to t=0 (Isc stimulated--Isc at t=0) is represented for vehicle (closed down-pointing triangle), insulin (closed up-pointing triangle), and IGF-1-(closed square) treated cells (n=6). Increasing concentrations of hormone are represented by increasing size of the symbol (insulin: 0.3nM, 1nM, 10nM, 30nM, 100nM, and 1000nM; IGF-1: 10 pM, 0.1nM, 0.3nM, 1nM, 10nM, 30nM). At t=-2h, cells were fed with DMEM:F12 (1:1), and at t=0h insulin, IGF-1, or the vehicle, were added on the basolateral side. At the end of the experiment, 10μM amiloride was added to the apical side, that blocked 99% of the induced current (not shown). (c) Dose–response comparison for insulin (closed up-pointing triangle) and IGF-1 (closed square) at t=1h (time point of maximal stimulation, see Figure 1). The delta stimulated current (Isc stimulated-Isc control) of the induced current at t=1h is represented. The dotted line represents the dose–response curve as calculated, using the nonlinear fit routine of the Kaleidagraph® program. Kidney International 2007 71, 116-125DOI: (10.1038/sj.ki.5002018) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 3 Co-stimulation with 0.3nM aldosterone and 0.3nM IGF-1 or 30nM insulin induces an additive effect on sodium transport. Time course curves for co-stimulation with 0.3nM aldosterone and 0.3nM IGF-1 (a, n=9) or 30nM insulin (b, n=12). Cells were treated with: vehicle (closed down-pointing triangle), IGF-1 or insulin (closed square or closed up-pointing triangle, respectively), 0.3nM aldosterone (closed circle), or both aldosterone and IGF-1 or insulin (closed diamond). The delta of the induced current as respect to t=0 (Isc stimulated-Isc at t=0) is represented. The dotted line corresponds to the calculated additive effect of co-stimulation (control condition delta current+IGF-1 or insulin induction+aldosterone induction). Kidney International 2007 71, 116-125DOI: (10.1038/sj.ki.5002018) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 4 Co-stimulation with 300nM aldosterone and 0.3nM IGF-1 or 30nM insulin induces an additive effect on sodium transport only at t=1h. Time course curves for co-stimulation with 300nM aldosterone and 0.3nM IGF-1 (a, n=9) or 30nM insulin (b, n=9). Cells were treated with: vehicle (closed down-pointing triangle), IGF-1 or insulin (closed square or closed up-pointing triangle, respectively), 300nM aldosterone (closed circle), or both aldosterone and IGF-1 or insulin (closed diamond). The delta of the induced current as respect to t=0 (Isc stimulated-Isc at t=0) is represented. The dotted line corresponds to the calculated additive effect of co-stimulation (control condition delta current+IGF-1 or insulin induction+aldosterone induction). Kidney International 2007 71, 116-125DOI: (10.1038/sj.ki.5002018) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 5 IGF-1 induces an increase in Isc on cells pretreated for 5h with 0.3nM aldosterone. Dose–response curves for 1h stimulation with IGF-1 in cells pretreated (closed diamond) or not (closed square) with 0.3nM aldosterone for 5h (n=6). The absolute transepithelial current (Isc) value at t=1h of the IGF-1 stimulation is represented. Kidney International 2007 71, 116-125DOI: (10.1038/sj.ki.5002018) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 6 The PI3-K inhibitor LY294002 blocks the aldosterone and IGF-1 stimulated and co-stimulated current. Time course curves for co-stimulation with 0.3nM IGF-1, 50μM LY294002 and 0.3nM (a, n=6) or 300nM (b, n=6) aldosterone. Cells were treated with vehicle (down-pointing triangle), IGF-1 (square), aldosterone (circle), or both aldosterone and IGF-1 (closed diamond) in the absence (closed symbols) or presence (open symbols) of LY294002. The delta of the induced current as respect to t=0 (Isc stimulated-Isc at t=0) are shown. Kidney International 2007 71, 116-125DOI: (10.1038/sj.ki.5002018) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 7 Characterization of Sgk1 phosphorylation states and anti-Sgk antibody. mCCDcl1 cells were treated with 300nM aldosterone for 2h (a, first and second lanes), 300nM aldosterone and 50μM LY294002 for 2h (a, third and fourth lanes), or 0.3nM IGF-1 for 1h (b, two different samples) before lysis; lysis buffer did not contain phosphatase inhibitors. Lysates were treated with λ-phosphatase (NewEngland-BioLabs, Ipswich, MA, USA) or only the phosphatase buffer, during 30min at 30°C, and reactions were stopped by adding SDS-PAGE sample buffer and boiling at 95°C for 5min. Lysates were then analyzed by SDS-PAGE/Western blotting, using anti-Sgk (upper panels) and anti-actin (lower panels) antibodies. A 25μg portion of total protein was analyzed in the first two lanes of the a, and 50μg in the third and fourth lanes of the a, and on the b. A band that matches the calculated molecular weight of the non-phosphorylated Sgk1 (48.9kDa) is indicated by an arrow head. Three more slowly migrating bands, presumably different phosphorylation states of Sgk1, are indicated by a bracket. A nonspecific band is indicated by a star. Kidney International 2007 71, 116-125DOI: (10.1038/sj.ki.5002018) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 8 A basolateral, but not an apical treatment with IGF-1, induces an increase in Sgk1 expression and phosphorylation. mCCDcl1 cells were treated with vehicle (lane 1), 10nM IGF-1 on the apical side (lane 2), 0.1nM IGF-1 on the basolateral side (lane 3) or 10nM IGF-1 on the basolateral side (lane 4) for 1h before electrophysiological measurements and lysis. Lysates were then analyzed by SDS-PAGE/Western blotting using anti-Sgk and anti-actin antibodies. (a) A representative blot of five independent experiments is shown. Non-phosphorylated Sgk1 (48.9kDa) is indicated by an arrow head, and different putative phosphorylation states of Sgk1 by a bracket. (b) Total Sgk1 expression levels were quantified and normalized to actin expression levels (open bars); control condition was considered 100% expression. (c) Blot and quantification results are correlated with the treatment-induced current increase (delta of the induced current as respect to t=0 (Isc stimulated-Isc at t=0)) at the same time point as the Western blotting data. Kidney International 2007 71, 116-125DOI: (10.1038/sj.ki.5002018) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 9 Co-stimulation with 0.3nM aldosterone and 0.3nM IGF-1, either simultaneously or adding IGF-1 after a 5h aldosterone pretreatment, induces an additive effect on Sgk1 protein expression and phosphorylation. (a, c, e): mCCDcl1 cells were treated with IGF-1 vehicle (lanes 1 and 4), 0.1nM IGF-1 (lanes 2 and 5) or 10nM IGF-1 (lanes 3 and 6) for 1h after a 5h pretreatment with aldosterone vehicle (lanes 1–3) or 0.3nM (lanes 4–6), before electrophysiological measurements and lysis. (b, d, f) mCCDcl1 cells were treated with vehicle (lane 1), 50μM LY294002 (lane 2), 0.3nM IGF-1 (lane 3), 0.3nM aldosterone (lane 4), both IGF-1 and aldosterone (lane 5), IGF-1 and LY294002 (lane 6), aldosterone and LY294002 (lane 7) or aldosterone, IGF-1 and LY294002 (lane 8) for 2h before electrophysiological measurements and lysis. In both experiments, lysates were then analyzed by SDS-PAGE/Western blotting, using anti-Sgk and anti-actin antibodies. A representative blot of two independent experiments is shown (upper panels). Non-phosphorylated Sgk1 (48.9kDa) is indicated by an arrow head, and different putative phosphorylation states of Sgk1 by a bracket. Total Sgk1 expression levels were quantified and normalized to actin expression levels (middle panels, open bars); control condition was considered 100% expression. Blot and quantification results are correlated with the treatment-induced current increase (delta of the induced current as respect to t=0 (Isc stimulated-Isc at t=0)) at the same time point as the Western blotting figures (lower panels). Kidney International 2007 71, 116-125DOI: (10.1038/sj.ki.5002018) Copyright © 2007 International Society of Nephrology Terms and Conditions

Figure 10 Co-stimulation with 300nM aldosterone and 0.3nM IGF-1 simultaneously induces an additive effect on Sgk1 expression and phosphorylation, but not when adding IGF-1 after a 5h 300nM aldosterone pretreatment. (a, c) mCCDcl1 cells were treated with IGF-1 vehicle (lanes 1 and 4), 0.1nM IGF-1 (lanes 2 and 5) or 10nM IGF-1 (lanes 3 and 6) for 1h after a 5h pretreatment with aldosterone vehicle (lanes 1–3) or 300nM (lanes 4–6), before electrophysiological measurements and lysis. (b, d) mCCDcl1 cells were treated with 300nM aldosterone (lane 1), both 0.3nM IGF-1 and 300nM aldosterone (lane 2), 300nM aldosterone and 50μM LY294002 (lane 3) or aldosterone, IGF-1, and LY294002 (lane 4) for 2h before electrophysiological measurements and lysis. In both experiments, lysates were then analyzed by SDS-PAGE/Western blotting using anti-Sgk and anti-actin antibodies. Non-phosphorylated Sgk1 (48.9kDa) is signaled by an arrow head and different putative phosphorylation states of Sgk1 by a bracket (upper panels). The figure shows a representative blot of two independent experiments correlated with graph showing the treatment-induced current increase (delta of the induced current as respect to t=0 (Isc stimulated-Isc at t=0)) (lower panels, closed bars) at the same time point as the Western blotting figures. Kidney International 2007 71, 116-125DOI: (10.1038/sj.ki.5002018) Copyright © 2007 International Society of Nephrology Terms and Conditions